Skip to main content
. 2015 Sep 9;48(2):508–517. doi: 10.4143/crt.2015.172

Fig. 3.

Fig. 3.

Relapse-free survival rates in the entire cohort (n=109) (A, B) and locoregional recurrence-free survival (C) in the no post-mastectomy radiotherapy cohort (n=72), according to high (≥ 5.36) and low (< 5.36) maximum standardized uptake value (SUVmax) of whole body tumors (WT) (SUVmax WT), the primary tumor (Br) (SUVmax Br), or the axillary lymph nodes (LN) (SUVmax LN).